Cited by 1,308Cancer-related Molecular PathwaysChromatin Remodeling and CancerPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 57 of the 64 references it cites were found in a registry or an index.

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Open access

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell

DOI 10.1016/j.cell.2004.11.004

Open this paper in CoChat — free account Open PDF

Abstract

The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53R172H and the contact mutant p53R270H (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53R270H/+ and p53R172H/+ mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53+/- mice. In addition, p53R270H/- and p53R172H/- mice developed novel tumors compared to p53-/- mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53R270H/+ and p53R172H/+ mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2004.11.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities
Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,118
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987

Flagged first, then by citations

Show all 64 references

7 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells, Cell Growth Differ, 1, 571
Kleihues, 1997, Tumors associated with p53 germline mutations, Am. J. Pathol, 150, 1

Sorted by citations

Items 901–1,000 of 1,000

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
Fey, S. K., Najumudeen, A. K., Watt, D. M., Millett, L. M., Ford, C. A., Gilroy, K. L., Simpson, R. J., McLay, K., Upstill‐Goddard, R., Chang, D. K.-F., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2709 · Cited by 11
Interaction of p53 with the Δ133p53α and Δ160p53α isoforms regulates p53 conformation and transcriptional activity
Tomas, F., Roux, P., & Gire, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07213-4 · Cited by 11
MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization
Walker, C. J., Rush, C. M., Dama, P., O’Hern, M. J., Cosgrove, C. M., Gillespie, J. L., Zingarelli, R. A., Smith, B., Stein, M. E., Mutch, D. G., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx238 · Cited by 11
PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer
Fares, F., Berger, L., Girsh, E., Kakun, R. R., Ghannam-Shahbari, D., Tabach, Y., Zohar, Y., Gottlieb, E., & Perets, R. (2021) · Oncogene · doi:10.1038/s41388-021-01925-z · Cited by 11
Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
Luo, M. B., Huang, M., Yang, N., Zhu, Y., Huang, P., Xu, Z., Wang, W., & Cai, L. (2023) · Bone Research · doi:10.1038/s41413-023-00265-w · Cited by 11
Transgenic mouse model expressing P53R172H, luciferase, EGFP and KRASG12D in a single open reading frame for live imaging of tumor
Ju, H.-L., Calvisi, D. F., Moon, H., Baek, S., Ribback, S., Dombrowski, F., Cho, K. J., Chung, S. I., Han, K., & Ro, S. W. (2015) · Scientific Reports · doi:10.1038/srep08053 · Cited by 11
SnapShot: Genetic Mouse Models of Cancer
Zender, L., Zuber, J. A., & Lowe, S. W. (2007) · Cell · doi:10.1016/j.cell.2007.05.013 · Cited by 11
Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis
Slee, E. A., & Lü, X. (2013) · Scientific Reports · doi:10.1038/srep03105 · Cited by 10
ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation
Morton, D. J., Patel, D., Joshi, J., Hunt, A., Knowell, A. E., & Chaudhary, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13701 · Cited by 11
Gain of function in the mouse model of a recurrent mutation p53N236S promotes the formation of double minute chromosomes and the oncogenic potential of p19ARF
Zhao, L., Wang, B., Zhao, X., Wu, X., Zhang, Q., Wei, C., Shi, M.-L., Li, Y., Tang, W., Zhang, J., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22737 · Cited by 11
The role of p63 in epidermal morphogenesis and neoplasia
McDade, S. S., & McCance, D. J. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380223 · Cited by 11
Mutational hotspots in the TP53gene and, possibly, other tumor suppressors evolve by positive selection
Glazko, G. V., Babenko, V. N., Koonin, E. V., & Rogozin, I. B. (2006) · Biology Direct · doi:10.1186/1745-6150-1-4 · Cited by 11
The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice
Baldauf, C., Jeschke, A., Kanbach, V., Catalá-Lehnen, P., Baumhoer, D., Gerull, H., Buhs, S., Amling, M., Nollau, P., Harroch, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137745 · Cited by 11
Current methods in mouse models of pancreatic cancer.
Mazur, P., Herner, A., Neff, F., & Siveke, J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_9 · Cited by 11
S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis
Yuan, W., Goldstein, L. D., Durinck, S., Chen, Y., Nguyen, T. T., Kljavin, N. M., Sokol, E. S., Stawiski, E. W., Haley, B., Ziai, J. M., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1238-5 · Cited by 11
The Enigma of p53Preprint
Lozano, G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031062 · Cited by 11
Are TP53 mutations all alike?
Wong, T. N., & Link, D. C. (2024) · Hematology · doi:10.1182/hematology.2024000556 · Cited by 11
Genetic predisposition in sarcomas: clinical implications and management
Connolly, E. A., Boye, K., Bonvalot, S., Kratz, C. P., Leithner, A., Malkin, D. M., Messiou, C., Miah, A. B., Pantziarka, P., Timmermann, B., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103203 · Cited by 11
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer
Tseng, Y.-H., Tran, T. Q., Chang, J. T., Huang, Y., Nguyen, A. T., Chang, I. Y., Chen, Y., Hsieh, H.-W., Juang, Y.-L., Chang, P. M.-H., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02300-7 · Cited by 11
Genome-wide studies of the transcriptional regulation by p53
Li, M., He, Y., Feng, X., & Huang, J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.02.002 · Cited by 10
Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome
Wang, P., Ma, J., Li, J., Starost, M. F., Wolfgang, M. J., Singh, K., Pirooznia, M., Kang, J., & Hwang, P. M. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0368 · Cited by 10
TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression
Wang, C., Zhang, S., Ma, B., Fu, Y., & Luo, Y. (2022) · Oncogene · doi:10.1038/s41388-022-02260-7 · Cited by 10
Genetic Alterations and Microenvironment that Drive Malignant Progression of Colorectal Cancer: Lessons from Mouse and Organoid Models
Nakayama, M., Wang, D., Kok, S. Y., Oshima, H., & Oshima, M. (2022) · Journal of Cancer Prevention · doi:10.15430/jcp.2022.27.1.1 · Cited by 10
Distinct target genes and effector processes appear to be critical for p53-activated responses to acute DNA damage versus p53-mediated tumour suppression
Valent, L., & Strasser, A. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.3 · Cited by 12
A platform for interrogating cancer-associated p53 alleles
D’Brot, A., Kurtz, P., Regan, E. A., Jakubowski, B., & Abrams, J. (2016) · Oncogene · doi:10.1038/onc.2016.48 · Cited by 11
Cooperation of p53 Mutations with Other Oncogenic Alterations in Cancer
Girardini, J. E., Walerych, D., & Sal, G. D. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_3 · Cited by 10
p53 in the Clinics
Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains
Park, D., Shakya, R., Koivisto, C. S., Pitarresi, J. R., Szabolcs, M. J., Kladney, R. D., Hadjis, A. D., Mace, T. A., & Ludwig, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226714 · Cited by 10
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models
Ramelow, J., Brooks, C. D., Gao, L., Almiman, A., Williams, T. M., Villalona-Calero, M. A., & Duan, W. (2020) · BMC Cancer · doi:10.1186/s12885-020-07212-6 · Cited by 10
Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion
Guo, A. K., Itahana, Y., Seshachalam, V. P., Chow, H. Y., Ghosh, S., & Itahana, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01124-9 · Cited by 10
Limited importance of the dominant-negative effect of TP53missense mutations
Stoczyńska-Fidelus, E., Szybka, M., Piaskowski, S., Bieńkowski, M., Hułas-Bigoszewska, K., Banaszczyk, M., Zawlik, I., Jesionek‐Kupnicka, D., Kordek, R., Liberski, P. P., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-243 · Cited by 10
Activité dominante négative des protéines p53 mutées
Dridi, W., Krabchi, K., Gadji, M., Lavoie, J., Bronsard, M., Fetni, R., & Drouin, R. (2006) · médecine/sciences · doi:10.1051/medsci/2006223301 · Cited by 10
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration
Larsson, C. A., Moyer, S. M., Liu, B., Michel, K. A., Pant, V., Yang, P., Wong, J., El‐Naggar, A. K., Krahe, R., & Lozano, G. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719001115 · Cited by 10
Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 + T cells dependent mannerPreprint
Mahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Diaz, B. A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528757 · Cited by 10
Mutant p53 and ELK1 co‐drive FRA ‐1 expression to induce metastasis in breast cancer
Hu, S., Wang, M., Ji, A., Yang, J., Gao, R., Li, X., Sun, L., Wang, J., Zhang, Y., & Liu, H. (2023) · FEBS Letters · doi:10.1002/1873-3468.14774 · Cited by 9
TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer
Urbach, L., Wieland, L., Penz, F., Samuel, R. D., Küffer, S., Klein, L., Lenz, C., Sax, U., Ghadimi, M. B., Schulz‐Heddergott, R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2339 · Cited by 10
TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma
van Kempen, P. M. W., Verdam, F. J., de Poel, E., Braunius, W. W., de Weger, R. A., van Es, R. J. J., Grolman, W., & Willems, S. M. (2015) · Pathobiology · doi:10.1159/000369102 · Cited by 10
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
Mejía-Hernández, J. O., Raghu, D., Caramia, F., Clemons, N. J., Fujihara, K. M., Riseborough, T., Teunisse, A. F. A. S., Jochemsen, A. G., Abrahmsén, L., Blandino, G., et al. (2022) · Cancers · doi:10.3390/cancers14163947 · Cited by 10
Regulation of immunological tolerance by the p53-inhibitor iASPP
Akama‐Garren, E. H., Miller, P., Carroll, T. M., Tellier, M., Sutendra, G., Buti, L., Zaborowska, J., Goldin, R. D., Slee, E. A., Szele, F. G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05567-9 · Cited by 8
Defining function of wild-type and three patient-specific TP53 mutations in a zebrafish model of embryonal rhabdomyosarcoma
Chen, J., Baxi, K., Lipsitt, A. E., Hensch, N. R., Wang, L., Sreenivas, P., Modi, P. S., Zhao, X. R., Baudin, A., Robledo, D. G., et al. (2023) · eLife · doi:10.7554/elife.68221 · Cited by 9
Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy
Oak, S., Karajgikar, O., & Teni, T. R. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.08.016 · Cited by 9
Modeling of Intracellular Taurine Levels Associated with Ovarian Cancer Reveals Activation of p53, ERK, mTOR and DNA-Damage-Sensing-Dependent Cell Protection
Centeno, D., Farsinejad, S., Kochetkova, E. Y., Volpari, T., Gładych-Macioszek, A., Klupczyńska-Gabryszak, A., Polotaye, T., Greenberg, M., Kung, D., Hyde, E., et al. (2024) · Nutrients · doi:10.3390/nu16121816 · Cited by 10
The p53R172H Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
Ahronian, L. G., Driscoll, D. R., Klimstra, D. S., & Lewis, B. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123816 · Cited by 9
A novel molecular rotor facilitates detection of p53-DNA interactions using the Fluorescent Intercalator Displacement Assay
Goh, W. L., Lee, M. Y., Lim, T. X., Chua, J. S., Brenner, S., Ghadessy, F. J., & Teo, Y. N. (2018) · Scientific Reports · doi:10.1038/s41598-018-31197-9 · Cited by 10
The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer
Napoli, M., & Flores, E. R. (2020) · RNA Biology · doi:10.1080/15476286.2019.1710054 · Cited by 10
Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression
Aiderus, A., Newberg, J. Y., Guzman‐Rojas, L., Contreras-Sandoval, A. M., Meshey, A. L., Jones, D. J., Amaya‐Manzanares, F., Rangel, R., Ward, J. M., Lee, S.-C., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009094 · Cited by 9
Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
Lai, C. W., Xie, C., Raufman, J., & Xie, G. (2022) · Cancers · doi:10.3390/cancers14010219 · Cited by 9
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Rahmé, R., Braun, T., Manfredi, J. J., & Fenaux, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041152 · Cited by 9
Clinical Significance of PICT1 in Patients of Hepatocellular Carcinoma with Wild-Type TP53
Ishibashi, M., Kogo, R., Shibata, K., Ueo, H., Uchi, R., Matsumura, T., Takano, Y., Sawada, G., Takahashi, Y., Mima, K., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2958-x · Cited by 9
Recombinant Adenoviral Vectors Can Induce Expression of p73 via the E4-orf6/7 Protein
Shapiro, G. S., Peursem, C. V., Ornelles, D. A., Schaack, J. B., & DeGregori, J. V. (2006) · Journal of Virology · doi:10.1128/jvi.02016-05 · Cited by 8
p53: Balancing tumour suppression and implications for the clinic
Buganim, Y., & Rotter, V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70037-1 · Cited by 9
Transforming growth factor-beta and mutant p53 conspire to induce metastasis by antagonizing p63: a (ternary) complex affair
Marine, J., & Berx, G. (2009) · Breast Cancer Research · doi:10.1186/bcr2337 · Cited by 9
TP53 as clinical marker in head and neck cancer
Peltonen, J. K. (2011) · Cited by 9
Evasion of cell senescence in SHH medulloblastoma
Tamayo-Orrego, L., Swikert, S. M., & Charron, F. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1189044 · Cited by 9
Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia
Fırtına, S., Erbilgin, Y., Ng, Ö. H., Karaman, S., Karakaş, Z., Celkan, T. T., Gelen, S. A., Yildirmak, Y., Özbek, U., & Sayitoğlu, M. (2023) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2023.2195682 · Cited by 8
The Janus kinase 1 is critical for pancreatic cancer initiation and progression
Shrestha, H., Rädler, P. D., Dennaoui, R., Wicker, M. N., Rajbhandari, N., Sun, Y., Peck, A. R., Vistisen, K. S., Triplett, A. A., Beydoun, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114202 · Cited by 8
Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation
Wang, L., Zhong, S., Fan, X., Xu, Y., Wang, M., Xu, Y., Cai, Y., Cao, Z., Ye, Z., Wen, L., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103522 · Cited by 8
KRASG12D Cells Override Homeostatic Cell Elimination Mechanisms in Adult Pancreas Via Wnt5a and Cell Dormancy
Salvador-Barberó, B., Alatsatianos, M., Morton, J. P., Sansom, O. J., & Hogan, C. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.042 · Cited by 8
Non-canonical p53 signaling to promote invasion
Dent, P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26174 · Cited by 8
Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review
Irshaid, L., Clark, M. B., Fadare, O., Finberg, K. E., & Parkash, V. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000792 · Cited by 8
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis
Ran, R., Li, L., Shi, Z., Liu, G., Jiang, H., Fang, L., Xu, T., Huang, J., Chen, W., & Chen, Y. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13301 · Cited by 7
Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo
Xue, Y., Luis, B. S., Dress, R. J., Murad, K. B. A., Ginhoux, F., Barker, N., & Lane, D. P. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219978120 · Cited by 8
Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Chachad, D., Patel, L. R., Recio, C. V., Pourebrahim, R., Whitley, E. M., Wang, W., Su, X., Xu, A., Lee, D., & Lozano, G. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3464 · Cited by 8
Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?
Ntenti, C., Lallas, K., & Papazisis, G. (2023) · Diagnostics · doi:10.3390/diagnostics13111915 · Cited by 8
TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states
Panzeri, I., Fagnocchi, L., Apostle, S., Tompkins, M., Wolfrum, E., Madaj, Z., Hostetter, G. H., Liu, Y., Schaefer, K., Yang, C.-H., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00900-3 · Cited by 8
Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hyposmotic Pressure
Shi, M., Shtraizent, N., Polotskaia, A., Bargonetti, J., & Matsui, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099351 · Cited by 8
Modeling of osteosarcoma with induced pluripotent stem cells
Pang, L. K., Pena, M., Zhao, R., & Lee, D. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102006 · Cited by 8
Dual recombinase action in the normal and neoplastic mammary gland epithelium
Rädler, P. D., Vistisen, K. S., Triplett, A. A., Dennaoui, R., Li, Y., Shrestha, H., Ferraiuolo, R., Thangasamy, A., Saur, D., & Wagner, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-00231-8 · Cited by 8
Frequent loss of metastatic ability in subclones of Apc, Kras, Tgfbr2, and Trp53 mutant intestinal tumor organoids
Morita, A., Nakayama, M., Wang, D., Murakami, K., & Oshima, M. (2022) · Cancer Science · doi:10.1111/cas.15709 · Cited by 8
Common activities and predictive gene signature identified for genetic hypomorphs of TP53
Leung, J. C., Leu, J. I.-J., Indeglia, A., Kannan, T., Clarke, N. L., Kirven, N. A., Dweep, H., Garlick, D., Barnoud, T., Kossenkov, A. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212940120 · Cited by 8
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
Miller, P., Akama‐Garren, E. H., Owen, R. P., Demetriou, C., Carroll, T. M., Slee, E. A., Moussawi, K. A., Ellis, M., Goldin, R. D., O’Neill, E. E., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01168-3 · Cited by 8
Mutant p53R211* ameliorates inflammatory arthritis in AIA rats via inhibition of TBK1-IRF3 innate immune response
Zeng, Y., Ng, J. P. L., Wang, L., Xu, X., Law, B. Y. K., Chen, G., Lo, H. H., Yang, L., Yang, J., Zhang, L., et al. (2023) · Inflammation Research · doi:10.1007/s00011-023-01809-w · Cited by 10
TAp63: The fountain of youth
Su, X., & Flores, E. R. (2009) · Aging · doi:10.18632/aging.100095 · Cited by 8
Genotoxic exposure: novel cause of selection for a functional ΔN-p53 isoform
Melis, J., Hoogervorst, E. M., van Oostrom, C. T. M., Zwart, E., Breit, T. M., Pennings, J. L. A., de Vries, A., & STEEG, H. V. (2010) · Oncogene · doi:10.1038/onc.2010.552 · Cited by 8
Sense out of missense
Dyke, T. V. (2005) · Nature · doi:10.1038/434287a · Cited by 8
MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer
Wang, X., He, X., Gao, T., Zhou, X., Cruz‐Monserrate, Z., Tsung, A., Ma, J., & Cai, C. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102118 · Cited by 7
Dependence on Mdm2 for Mdm4 inhibition of p53 activity
Xiong, S., Zhang, Y., Zhou, X., Pant, V., Mirani, A., Gencel‐Augusto, J., Chau, G. P., You, M. J., & Lozano, G. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217622 · Cited by 8
Modulating the Immunosuppressive Tumor Microenvironment and Inhibiting Growth in Mutp53-Driven CRPC via STAT3 Pathway Blockade
Bian, Z., Chen, J., Wang, Y., Jin, C., Liang, C. Y., Meng, J., & Zhang, M. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.111732 · Cited by 8
Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas
Imle, R., Blösel, D., Kommoss, F. K. F., Placke, S., Stutheit-Zhao, E., Blume, C., Lupar, D., Schmitt, L., Winter, C., Wagner, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60519-5 · Cited by 9
ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis
Salomo-Coll, C., Monaco, M. D., Holkham, J., Smith, M. D., Muir, M., Gautier, P. E., Dunn-Davies, H., Zheng, X., Krishnankutty, R., Kemp, A. J., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.07.016 · Cited by 8
The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis
Fullin, J., Topçu, E., Zielińska, K. A., Schimmer, R. R., Klemm, N., Koch, C., Caiado, F., Lock, M., Doerdelmann, C., Bühler, M. M., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02839-5 · Cited by 9
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Than, M. T., Dequiedt, L., Sor, R., Nair, S., Markosyan, N., Furth, E. E., Yang, C., Ray-Fofana, C., Menard, M. J., Quintana, E., et al. (2026) · Science · doi:10.1126/science.aec7929 · Cited by 9
Targeting cancer-specific mutations with RNA-triggered chromatin shredding
Zeng, J., Cheng, Z., Chen, H., Wang, Z., Thompson, J., Crosby, K. T., Han, H., Singhal, A., Ngo, W., Xia, C., et al. (2026) · Nature · doi:10.1038/s41586-026-10738-7 · Cited by 8
Clinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan
Wu, K.-S., Sung, S., Huang, M., Lin, Y., Chang, C., Fang, C., Wong, T., Chen, H., & Tsai, M. (2022) · Cancers · doi:10.3390/cancers14215419 · Cited by 7
p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications
Benitez, D. A., Cumplido-Laso, G., Olivera-Gómez, M., Pino, N. D. V.-D., Díaz-Pizarro, A., Mulero‐Navarro, S., Román-García, A., & Carvajal-González, J. M. (2024) · Biomedicines · doi:10.3390/biomedicines12071453 · Cited by 9
Missense Mutant p53 Transactivates Wnt/β-Catenin Signaling in Neighboring p53-Destabilized Cells through the COX-2/PGE2 Pathway
Nakayama, M., Saito, H., Murakami, K., Oshima, H., & Oshima, M. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0471 · Cited by 7
p53 in Head and Neck Squamous Cell Carcinoma
Philips, R. H. W., & Pan, Q. (2017) · Springer eBooks · doi:10.1007/978-94-024-1084-6_5 · Cited by 7
Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for li-fraumeni syndrome
Wang, Y., Wang, Z., Cormier, R., Miao, J., Li, R., Wettere, A. V., Guo, H., Tăbăran, F., O'Sullivan, M., Carlson, T., et al. (2021) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_18_21 · Cited by 7
Low-dose but not high-dose γ-irradiation elicits the dominant-negative effect of mutant p53 in vivo
Ghaleb, A., Roa, L., & Marchenko, N. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.018 · Cited by 8
Genetically Engineered Mouse Models for Human Lung Cancer
Inoue, K., Fry, E. A., Maglic, D., & Zhu, S. (2013) · InTech eBooks · doi:10.5772/53721 · Cited by 8
Mutant p53 Cooperates with Knockdown of Endogenous Wild-Type p53 to Disrupt Tubulogenesis in Madin-Darby Canine Kidney Cells
Zhang, Y., Yan, W., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085624 · Cited by 7
Mouse Models of Inherited Cancer Syndromes
Jahid, S., & Lipkin, S. M. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.011 · Cited by 7
Detection of Ovarian Cancer Using Samples Sourced from the Vaginal Microenvironment
Galey, M. M., Young, A. N., Petukhova, V. Z., Wang, M., Wang, J., Salvi, A., Russo, A., Burdette, J. E., & Sanchez, L. M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00694 · Cited by 7
Genetic Mouse Models of Cancer
Winslow, M. M., & Jacks, T. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00009-3 · Cited by 7
Tumor Suppressor Genes
Cosgrove, D., Park, B. H., & Vogelstein, B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm005 · Cited by 7
Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation
Fuchs, S. N. R., Stalmann, U., Snoeren, I., Bindels, E. M., Schmitz, S., Banjanin, B., Hoogenboezem, R. M., van Herk, S., Saad, M., Walter, W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008926 · Cited by 6
Differential Effects of Trp53 Alterations in Murine Colorectal Cancer
Betzler, A. M., Nanduri, L. K., Hissa, B., Blickensdörfer, L., Muders, M. H., Roy, J., Jesinghaus, M., Steiger, K., Weichert, W., Kloor, M., et al. (2021) · Cancers · doi:10.3390/cancers13040808 · Cited by 6
Reduced sister chromatid cohesion acts as a tumor penetrance modifier
Wang, J., Thomas, H. R., Chen, Y., Percival, S. M., Waldrep, S. C., Ramaker, R. C., Thompson, R. G., Cooper, S. J., Chong, Z., & Parant, J. M. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010341 · Cited by 7
Combined germline pathogenic variants in FLCN and TP53 are associated with early onset renal cell carcinoma and brain tumors
van de Beek, I., Glykofridis, I. E., Wagner, A., den Toom, D. T., Bongers, E. M. H. F., van Leenders, G. J. L. H., Johannesma, P. C., Meijers-Heijboer, H. E. J., Wolthuis, R. M. F., Steensel, M. A. M. V., et al. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2098 · Cited by 6
Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo
Shimizu, T., Sugihara, E., Takeshima, H., Nobusue, H., Yamaguchi, R., Yamaguchi‐Iwai, S., Fukuchi, Y., Ushijima, T., Muto, A., & Saya, H. (2022) · Cells · doi:10.3390/cells11223614 · Cited by 6

Authors: Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T.
Affiliations: Massachusetts Institute of Technology (US)
Abramson Cancer Center (US)
Tufts University (US)
Howard Hughes Medical Institute (US)
Corresponding author: Jacks, Tyler
ORCID: Olive, Kenneth P.
Tuveson, David A.
Ruhe, Zachary C.
Willis, Nicholas A.
Bronson, Roderick T.
Jacks, Tyler
Venue: Cell
Publisher: Elsevier BV
Published: 2004-12
Volume: 119
Issue: 6
Pages: 847-860
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2004.11.004
OpenAlex: W2079852484
Cited by: 1,308
References: 64
Citations by year: 2026: 26 · 2025: 49 · 2024: 52 · 2023: 87 · 2022: 52 · 2021: 64 · 2020: 67 · 2019: 69 · 2018: 74 · 2017: 69 · 2016: 78 · 2015: 75 · 2014: 97 · 2013: 64 · 2012: 51
FWCI: 21.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3150 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, Li-Fraumeni syndrome, gain-of-function mutations, missense mutations, dominant-negative p53, tumor suppressor, mouse model, endothelial tumors, carcinoma, oncogenicity
MeSH terms: Alleles, Animals, Carcinoma, Mice, Transgenic, Mutation, Neoplasms, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Genes, p53, Li-Fraumeni Syndrome, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks